MoneyAM

Vectura Group Share Price (VEC)

120.50 +2.75 (+2.34%) delayed: 7:57AM BST
Bid price 118.25 Open price 0.00
Ask price 122.75 Prev close 117.75
High price 0.00 Spread 3.67%
Low price 0.00 Volume 0

Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.

Vectura Group Share Price Chart

Advanced Charts >>

Register now for FREE Vectura Group share price charts

Vectura Group Share Price Information

Name Vectura Group Epic VEC
Sector Pharmaceuticals & Biotechnology ISIN GB00B01D1K48
Activites Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. Index n/a

Vectura Group Key Numbers

Latest Share Price (p) 120.50 Net Gearing (%) -31.37
Market Capitalisation (£m) 504.08 Gross Gearing (%) 13.51
Shares in issue (m) 399.65 Debt Ratio 0.95
P/E Ratio -70.07 Debt-to-Equity Ratio 0.06
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.16
Dividend Yield (%) 0.00 Price to book value 3.73
Dividend cover (x) 0.00 ROCE -0.13
Earning per share (p) -1.80 EPS Growth (%) -38.46
52 week high / low 171.50 / 76.00 DPS Growth (%) n/a

Vectura Group Director Deals

Dec.Date Type Director Pos No. of Shares
13/03/2014 PLAC Dr Christopher Blackwell CEO 16,129
13/03/2014 PLAC Dr Trevor Phillips ED 6,452
13/03/2014 PLAC Paul Oliver FD 6,452
13/03/2014 PLAC Bruno Angelici NED 12,903
13/03/2014 PLAC Neil Warner NED 9,677

More Vectura Group Director Deals >>

Vectura Group Company News

07:37 11/04/2014

Vectura to initiate Europe study for asthma drug Favolir

Vectura Group is to initiate a pivotal study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma. This decision underlines Vectura's planned strategy for a broad European development programme for Favolir, rather than a country-specific...

07:10 11/04/2014

FLASH: Vectura to initiate Europe study for asthma drug Favolir

Story provided by StockMarketWire.com

07:00 11/04/2014

FAVOLIR Regulatory Update

/* */ RNS Number : 5869E Vectura Group plc 11 April 2014      Vectura Group plc FAVOLIR Regulatory Update     Chippenham, UK - 11 April 2014: Vectura Group plc (LSE: VEC; "Vectura" or the "Company") announces that it will...

More Vectura Group Company News >>

Register now for FREE Vectura Group company news

Vectura Group Share Price Discussions

5 days ago

VECTURA (VEC)

Powered by IST's

Register now for FREE Vectura Group share price discussions